A share price of Transmedics Group Inc [TMDX] is currently trading at $87.11, up 8.06%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TMDX shares have gain 12.84% over the last week, with a monthly amount drifted -1.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on November 22, 2024, when Needham downgraded its rating to a Hold. Previously, Oppenheimer reaffirmed its Outperform rating on October 29, 2024, and dropped its price target to $125. On October 29, 2024, Needham reiterated its Buy rating and revised its price target to $109 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $200 on September 24, 2024. Needham initiated its recommendation with a Buy and recommended $208 as its price target on August 21, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on June 06, 2024, and assigned it a price target of $161. In a note dated June 04, 2024, Stephens initiated an Overweight rating and provided a target price of $151 on this stock.
Transmedics Group Inc experienced fluctuations in its stock price throughout the past year between $67.77 and $177.37. Currently, Wall Street analysts expect the stock to reach $126.75 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $87.11 at the most recent close of the market. An investor can expect a potential return of 45.51% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Trailing Twelve Months sales for Transmedics Group Inc [NASDAQ:TMDX] were 401.09M which represents 63.72% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 83.20 points at the first support level, and at 79.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 89.29, and for the 2nd resistance point, it is at 91.48.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Transmedics Group Inc [NASDAQ:TMDX] is 8.20. In addition, the Quick Ratio stands at 7.33 and the Cash Ratio stands at 5.5. Considering the valuation of this stock, the price to sales ratio is 7.88, the price to book ratio is 13.93 and price to earnings (TTM) ratio is 93.33.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Nov 11 ’24 when 1458.0 shares were sold. Director, Basile Edward M completed a deal on Nov 05 ’24 to sell 6750.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 1083.0 shares on Nov 01 ’24.
